Royalty expense calculated as a percentage of net sales.

No definition available.

Name:	nnvc_PercentageOfNetSalesAllocatedForRoyaltyPayments
Namespace Prefix:	nnvc_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

It represents the amount of stock issued during period, value, new issues, cash upon completion of phase I clinical trials.

+ References

No definition available.

+ Details

Name:	nnvc_StockIssuedDuringPeriodValueNewIssuesCashUponCompletionOfPhase1ClinicalTrials
Namespace Prefix:	nnvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

It represents the amount of stock issued during period, value, new issues, cash upon completion of phase II clinical trials.

+ References

No definition available.

+ Details

Name:	nnvc_StockIssuedDuringPeriodValueNewIssuesCashUponCompletionOfPhase2ClinicalTrials
Namespace Prefix:	nnvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

It represents the amount of stock issued during period, value, new issues, cash upon completion of phase III clinical trials.

+ References

No definition available.

+ Details

Name:	nnvc_StockIssuedDuringPeriodValueNewIssuesCashUponCompletionOfPhase3ClinicalTrials
Namespace Prefix:	nnvc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

+ Details

Name:	us-gaap_StockholdersEquityNoteStockSplitConversionRatio1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:pureItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nnvc_TheracourPharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=nnvc_SeriesAConvertiblePreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Organization and Nature of Business (Details)				12 Months Ended
Organization and Nature of Business (Details)	Mar. 25, 2020 shares	Nov. 01, 2019 USD ($) shares	Sep. 24, 2019	Jun. 30, 2020
Issuance of shares \| shares	180,087
Cash upon completion of Phase I Clinical Trials		$ 1,500,000
Cash upon completion of Phase II Clinical Trials		2,500,000
Cash upon completion of Phase III Clinical Trials		$ 5,000,000
Reverse stock split			20.00
Percentage of Net Sales Allocated for Royalty Payments				15.00%
TheraCour
Issuance of shares \| shares		75,000
Cash upon completion of Phase I Clinical Trials		$ 1,500,000
Cash upon completion of Phase II Clinical Trials		2,500,000
Cash upon completion of Phase III Clinical Trials		$ 5,000,000
Percentage of Net Sales Allocated for Royalty Payments		15.00%
Series A Convertible Preferred Stock [Member]
Issuance of shares \| shares		75,000
Reverse stock split				350